SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesmarket

BNXT (BNXT) News

Follow BNXT (BNXT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol BNXT Asset market Sector Markets 90 days 2 Updated Sep 08, 2026, 07:05 AM UTC Open live news feed
L BioNxt advances sublingual everolimus ODF for transplant rejection study BioNxt Solutions Inc. says it is advancing its proprietary sublingual everolimus oral dissolving film (ODF) for organ transplant rejection, and has initiated a large-animal pharmacokinetic study. EQUITY | Sep 08, 2026, 07:05 AM UTC L BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Cl BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies EQUITY | Aug 26, 2026, 07:05 AM UTC L BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway VANCOUVER, BC / / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:B EQUITY | Jul 06, 2026, 07:05 AM UTC L BNXT: Closes Private Placement BioNxt announces closing of non-brokered private placement of units EQUITY | Jun 23, 2026, 09:20 PM UTC